Teplizumab

Therapeutic indications

Teplizumab is indicated for:

Delay of the Stage 3 onset of type 1 diabetes

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Teplizumab is indicated to delay the onset of Stage 3 type 1 diabetes in adults and pediatric patients 8 years of age and older with Stage 2 type 1 diabetes.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Teplizumab is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Active serious infection, chronic infections other than localized skin infections

Infectious disease

Vaccinations

Vaccines

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2023: TZIELD Solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈